ASCs receive maximum allowable payments at 140 percent Medicare in addition to the “total cost of all surgical implants per case with certain revenue codes minus a $500 implant cost reduction per case,” according to the report. ASCs must include the original implant manufacturer’s wholesale invoice at the time of billing and adjust the invoice to reflect applicable rebates, discounts, and refunds, in addition to other things that may have reduced the original cost.
The new schedule went into effect in April.
